Morgan Stanley’s Enlivex Therapeutics ENLV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$245K Sell
219,149
-11,536
-5% -$12.9K ﹤0.01% 5772
2025
Q1
$224K Sell
230,685
-38,970
-14% -$37.8K ﹤0.01% 5686
2024
Q4
$315K Buy
269,655
+23,901
+10% +$28K ﹤0.01% 5613
2024
Q3
$413K Buy
245,754
+862
+0.4% +$1.45K ﹤0.01% 5489
2024
Q2
$348K Buy
244,892
+172,772
+240% +$245K ﹤0.01% 5453
2024
Q1
$273K Sell
72,120
-16,800
-19% -$63.7K ﹤0.01% 5602
2023
Q4
$240K Buy
88,920
+44,764
+101% +$121K ﹤0.01% 5876
2023
Q3
$69.8K Buy
44,156
+305
+0.7% +$482 ﹤0.01% 6028
2023
Q2
$115K Buy
43,851
+3,692
+9% +$9.7K ﹤0.01% 5886
2023
Q1
$146K Sell
40,159
-567
-1% -$2.06K ﹤0.01% 5846
2022
Q4
$160K Sell
40,726
-3,790
-9% -$14.9K ﹤0.01% 5758
2022
Q3
$189K Buy
44,516
+11,791
+36% +$50.1K ﹤0.01% 5750
2022
Q2
$148K Buy
32,725
+11,150
+52% +$50.4K ﹤0.01% 6045
2022
Q1
$121K Buy
21,575
+4,414
+26% +$24.8K ﹤0.01% 6201
2021
Q4
$107K Sell
17,161
-1,382
-7% -$8.62K ﹤0.01% 6400
2021
Q3
$183K Buy
18,543
+4,441
+31% +$43.8K ﹤0.01% 6050
2021
Q2
$126K Sell
14,102
-1,429
-9% -$12.8K ﹤0.01% 6247
2021
Q1
$172K Buy
15,531
+12,725
+453% +$141K ﹤0.01% 5747
2020
Q4
$24K Buy
+2,806
New +$24K ﹤0.01% 6375
2020
Q3
Sell
-2
Closed 6755
2020
Q2
$0 Sell
2
-28,147
-100% ﹤0.01% 6632
2020
Q1
$132K Buy
28,149
+28,147
+1,407,350% +$132K ﹤0.01% 5067
2019
Q4
$0 Hold
2
﹤0.01% 6677
2019
Q3
$0 Hold
2
﹤0.01% 6667
2019
Q2
$0 Hold
2
﹤0.01% 6671
2019
Q1
$0 Buy
+2
New ﹤0.01% 6616
2018
Q4
Sell
-63
Closed -$1K 6624
2018
Q3
$1K Buy
+63
New +$1K ﹤0.01% 6621
2017
Q3
Sell
-18
Closed 6550
2017
Q2
$0 Buy
+18
New ﹤0.01% 6602
2017
Q1
Sell
-13
Closed -$1K 6582
2016
Q4
$1K Hold
13
﹤0.01% 6430
2016
Q3
$1K Hold
13
﹤0.01% 6415
2016
Q2
$1K Buy
13
+12
+1,200% +$923 ﹤0.01% 6420
2016
Q1
$0 Buy
+1
New ﹤0.01% 6613
2015
Q2
Sell
-18
Closed -$4K 6668
2015
Q1
$4K Buy
18
+17
+1,700% +$3.78K ﹤0.01% 6368
2014
Q4
$0 Hold
1
﹤0.01% 6588
2014
Q3
$0 Buy
+1
New ﹤0.01% 6587